COVID-19 Impact on Global Proteasome Inhibitors for Multiple Myeloma Market Size, Status and Forecast 2020-2026

July 2020 | 99 pages | ID: C2A769B4B04DEN
QYResearch

Abstracts

This report focuses on the global Proteasome Inhibitors for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Proteasome Inhibitors for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• J&J
• Takeda
• Amgen

Market segment by Type, the product can be split into

• Bortezomib
• Carfilzomib
• Ixazomib
• Other

Market segment by Application, split into

• Hospital
• Drug Center
• Clinic
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Proteasome Inhibitors for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.
• To present the Proteasome Inhibitors for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Proteasome Inhibitors for Multiple Myeloma are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Proteasome Inhibitors for Multiple Myeloma Revenue
1.4 Market Analysis by Type
  1.4.1 Global Proteasome Inhibitors for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Bortezomib
  1.4.3 Carfilzomib
  1.4.4 Ixazomib
  1.4.5 Other
1.5 Market by Application
  1.5.1 Global Proteasome Inhibitors for Multiple Myeloma Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Drug Center
  1.5.4 Clinic
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Proteasome Inhibitors for Multiple Myeloma Industry Impact
  1.6.1 How the Covid-19 is Affecting the Proteasome Inhibitors for Multiple Myeloma Industry
    1.6.1.1 Proteasome Inhibitors for Multiple Myeloma Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Proteasome Inhibitors for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Proteasome Inhibitors for Multiple Myeloma Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Proteasome Inhibitors for Multiple Myeloma Market Perspective (2015-2026)
2.2 Proteasome Inhibitors for Multiple Myeloma Growth Trends by Regions
  2.2.1 Proteasome Inhibitors for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Proteasome Inhibitors for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  2.2.3 Proteasome Inhibitors for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Proteasome Inhibitors for Multiple Myeloma Market Growth Strategy
  2.3.6 Primary Interviews with Key Proteasome Inhibitors for Multiple Myeloma Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Proteasome Inhibitors for Multiple Myeloma Players by Market Size
  3.1.1 Global Top Proteasome Inhibitors for Multiple Myeloma Players by Revenue (2015-2020)
  3.1.2 Global Proteasome Inhibitors for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  3.1.3 Global Proteasome Inhibitors for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Proteasome Inhibitors for Multiple Myeloma Market Concentration Ratio
  3.2.1 Global Proteasome Inhibitors for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Proteasome Inhibitors for Multiple Myeloma Revenue in 2019
3.3 Proteasome Inhibitors for Multiple Myeloma Key Players Head office and Area Served
3.4 Key Players Proteasome Inhibitors for Multiple Myeloma Product Solution and Service
3.5 Date of Enter into Proteasome Inhibitors for Multiple Myeloma Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Proteasome Inhibitors for Multiple Myeloma Historic Market Size by Type (2015-2020)
4.2 Global Proteasome Inhibitors for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

5 PROTEASOME INHIBITORS FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)
5.2 Global Proteasome Inhibitors for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
6.2 Proteasome Inhibitors for Multiple Myeloma Key Players in North America (2019-2020)
6.3 North America Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
6.4 North America Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
7.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Europe (2019-2020)
7.3 Europe Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
7.4 Europe Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

8 CHINA

8.1 China Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
8.2 Proteasome Inhibitors for Multiple Myeloma Key Players in China (2019-2020)
8.3 China Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
8.4 China Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
9.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Japan (2019-2020)
9.3 Japan Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
9.4 Japan Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
10.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
10.4 Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

11 INDIA

11.1 India Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
11.2 Proteasome Inhibitors for Multiple Myeloma Key Players in India (2019-2020)
11.3 India Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
11.4 India Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Proteasome Inhibitors for Multiple Myeloma Market Size (2015-2020)
12.2 Proteasome Inhibitors for Multiple Myeloma Key Players in Central & South America (2019-2020)
12.3 Central & South America Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020)
12.4 Central & South America Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 J&J
  13.1.1 J&J Company Details
  13.1.2 J&J Business Overview and Its Total Revenue
  13.1.3 J&J Proteasome Inhibitors for Multiple Myeloma Introduction
  13.1.4 J&J Revenue in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020))
  13.1.5 J&J Recent Development
13.2 Takeda
  13.2.1 Takeda Company Details
  13.2.2 Takeda Business Overview and Its Total Revenue
  13.2.3 Takeda Proteasome Inhibitors for Multiple Myeloma Introduction
  13.2.4 Takeda Revenue in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020)
  13.2.5 Takeda Recent Development
13.3 Amgen
  13.3.1 Amgen Company Details
  13.3.2 Amgen Business Overview and Its Total Revenue
  13.3.3 Amgen Proteasome Inhibitors for Multiple Myeloma Introduction
  13.3.4 Amgen Revenue in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020)
  13.3.5 Amgen Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Proteasome Inhibitors for Multiple Myeloma Key Market Segments
Table 2. Key Players Covered: Ranking by Proteasome Inhibitors for Multiple Myeloma Revenue
Table 3. Ranking of Global Top Proteasome Inhibitors for Multiple Myeloma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Proteasome Inhibitors for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Bortezomib
Table 6. Key Players of Carfilzomib
Table 7. Key Players of Ixazomib
Table 8. Key Players of Other
Table 9. COVID-19 Impact Global Market: (Four Proteasome Inhibitors for Multiple Myeloma Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Proteasome Inhibitors for Multiple Myeloma Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Proteasome Inhibitors for Multiple Myeloma Players to Combat Covid-19 Impact
Table 14. Global Proteasome Inhibitors for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Proteasome Inhibitors for Multiple Myeloma Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Proteasome Inhibitors for Multiple Myeloma Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Regions (2015-2020)
Table 18. Global Proteasome Inhibitors for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Proteasome Inhibitors for Multiple Myeloma Market Growth Strategy
Table 24. Main Points Interviewed from Key Proteasome Inhibitors for Multiple Myeloma Players
Table 25. Global Proteasome Inhibitors for Multiple Myeloma Revenue by Players (2015-2020) (Million US$)
Table 26. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Players (2015-2020)
Table 27. Global Top Proteasome Inhibitors for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proteasome Inhibitors for Multiple Myeloma as of 2019)
Table 28. Global Proteasome Inhibitors for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Proteasome Inhibitors for Multiple Myeloma Product Solution and Service
Table 31. Date of Enter into Proteasome Inhibitors for Multiple Myeloma Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 34. Global Proteasome Inhibitors for Multiple Myeloma Market Size Share by Type (2015-2020)
Table 35. Global Proteasome Inhibitors for Multiple Myeloma Revenue Market Share by Type (2021-2026)
Table 36. Global Proteasome Inhibitors for Multiple Myeloma Market Size Share by Application (2015-2020)
Table 37. Global Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 38. Global Proteasome Inhibitors for Multiple Myeloma Market Size Share by Application (2021-2026)
Table 39. North America Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 41. North America Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 42. North America Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 43. North America Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 44. North America Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 45. Europe Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 47. Europe Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 49. Europe Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 51. China Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 52. China Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 53. China Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 54. China Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 55. China Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 56. China Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 57. Japan Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 59. Japan Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 61. Japan Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 65. Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 67. Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 69. India Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 70. India Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 71. India Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 72. India Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 73. India Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 74. India Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Proteasome Inhibitors for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Proteasome Inhibitors for Multiple Myeloma Market Share (2019-2020)
Table 77. Central & South America Proteasome Inhibitors for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Proteasome Inhibitors for Multiple Myeloma Market Share by Type (2015-2020)
Table 79. Central & South America Proteasome Inhibitors for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Proteasome Inhibitors for Multiple Myeloma Market Share by Application (2015-2020)
Table 81. J&J Company Details
Table 82. J&J Business Overview
Table 83. J&J Product
Table 84. J&J Revenue in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020) (Million US$)
Table 85. J&J Recent Development
Table 86. Takeda Company Details
Table 87. Takeda Business Overview
Table 88. Takeda Product
Table 89. Takeda Revenue in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020) (Million US$)
Table 90. Takeda Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Product
Table 94. Amgen Revenue in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020) (Million US$)
Table 95. Amgen Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Type: 2020 VS 2026
Figure 2. Bortezomib Features
Figure 3. Carfilzomib Features
Figure 4. Ixazomib Features
Figure 5. Other Features
Figure 6. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Drug Center Case Studies
Figure 9. Clinic Case Studies
Figure 10. Other Case Studies
Figure 11. Proteasome Inhibitors for Multiple Myeloma Report Years Considered
Figure 12. Global Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Regions: 2020 VS 2026
Figure 14. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Proteasome Inhibitors for Multiple Myeloma Market Share by Players in 2019
Figure 17. Global Top Proteasome Inhibitors for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proteasome Inhibitors for Multiple Myeloma as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Proteasome Inhibitors for Multiple Myeloma Revenue in 2019
Figure 19. North America Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Proteasome Inhibitors for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. J&J Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. J&J Revenue Growth Rate in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020)
Figure 28. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Takeda Revenue Growth Rate in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020)
Figure 30. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Amgen Revenue Growth Rate in Proteasome Inhibitors for Multiple Myeloma Business (2015-2020)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed